Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | LSS | P48449 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891107 | 0.90 | HPGD (0.36) | F10SMN1; SMN2TP53LSSLMNA | |
| SCHEMBL4890727 | 0.89 | HRH3 (0.40) | F10SMN1; SMN2TP53CNR1LSS | |
| SCHEMBL4894533 | 0.86 | HRH3 (0.35) | F10SMN1; SMN2TP53LMNAHPGD | |
| SCHEMBL4882732 | 0.86 | LSS (0.47) | F10SMN1; SMN2TP53CNR1LSS | |
| SCHEMBL4881800 | 0.85 | SMO (0.49) | F10SMN1; SMN2TP53CNR1LSS | |
| SCHEMBL4893503 | 0.84 | LSS (0.47) | F10SMN1; SMN2TP53CNR1LSS | |
| SCHEMBL4941429 | 0.83 | F10 (0.66) | F10SMN1; SMN2TP53CNR1LSS | |
| SCHEMBL4890700 | 0.82 | F2 (0.35) | F10SMN1; SMN2LMNAHPGDHRH3 | |
| SCHEMBL4892722 | 0.81 | HRH3 (0.34) | F10SMN1; SMN2TP53LMNAHPGD | |
| SCHEMBL4891898 | 0.81 | HRH3 (0.34) | F10SMN1; SMN2TP53LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | claimed |
| US-20080200431-A1 | 6-{4-[4-(3-Chloro-1H-indole-6-sulfonyl)-3-hydroxy-piperazine-1-carbonyl]-piperidin-1-yl}-2-methyl-2H-pyridazin-3-one for example; antithrombotic and anticoagulant; synthesis; combination therapy | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | claimed |
| WO-2007008143-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| WO-2007008146-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080200431-A1 | 6-{4-[4-(3-Chloro-1H-indole-6-sulfonyl)-3-hydroxy-piperazine-1-carbonyl]-piperidin-1-yl}-2-methyl-2H-pyridazin-3-one for example; antithrombotic and anticoagulant; synthesis; combination therapy | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| WO-2007008146-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008143-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200431-A1 | 6-{4-[4-(3-Chloro-1H-indole-6-sulfonyl)-3-hydroxy-piperazine-1-carbonyl]-piperidin-1-yl}-2-methyl-2H-pyridazin-3-one for example; antithrombotic and anticoagulant; synthesis; combination therapy | CYC1, F2, CBR1 | F10 27/4885SMN1; SMN2 4344/4885TP53 4364/4885 |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | F10, F12, F11 | F10 1/4885SMN1; SMN2 3963/4885TP53 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.